Patricia Van Arnum

Ian Lennox, chairman and CEO of Ricerca Biosciences, outlines the company's growth strategy post its acquisition of the discovery and preclinical business of MDS Pharma Services.

The US market for prescription drugs grew better than expected in 2009, but growth is still below historical levels.

Tablets and capsules are mainstay product forms, so what are the spending and innovation trends for solid-dosage manufacturing equipment and machinery?

Pharmaceutical Technology's annual survey on equipment and machinery reveals the spending levels and types of spending made in 2009 and planned for 2010.

Growth in the market for monoclonal antibodies, recombinant proteins, and vaccines creates new opportunities for drug companies and suppliers.

The US Government Accountability Office issued a report that's largely critical of FDA's efforts to fully use practices for effective strategic planning and management.

Biotechnology company Genzyme reported that FDA notified the company that it intends to take enforcement action to ensure that products are made in compliance with good manufacturing practice (GMP) regulations.

President Obama signed into law major healthcare reform following the passage of the bill by the House of Representatives.

AstraZeneca signed a license and supply agreement with the drug company and manufacturer Torrent Pharmaceuticals.

The Pharmaceutical Research and Manufacturers of America, along with eight other pharmaceutical, business, and trade organizations, are calling on Russian authorities to consider policy changes concerning clinical-trial regulation and intellectual property.

Merck KGaA has agreed to acquire Millipore for EUR 5.3 billion ($7.2 billion).

Nigel Darby, vice-president of biotechnologies at GE Healthcare Life Sciences and speaker at the Drug, Chemical, and Associated Technologies Association (DCAT) upcoming educational program on biologics, offers insight into the current and future state of upstream and downstream processing of biologics.

At last month's Informex, exhibitors announced expansions and new partnerships relating to contract manufacturing of active pharmaceuticals and intermediates and fine-chemicals supply.

Emerging markets remain an important element in the strategies of pharmaceutical companies and their suppliers.

Contract manufacturers report improving business conditions, but will they continue?

Analysis of the opportunities and challenges in the biosimilars market.

Pharmaceutical companies and their suppliers share approaches in risk mitigation in sourcing and ways to optimize the outsourced relationship.

The Society for Chemical Manufacturers and Affiliates offered its support for a Senate proposal to extend to 2015 current chemical-security standards, the Chemical Facility Anti-Terrorism Standards, which are set to expire this year.

Personalized medicine is still a nascent area for the pharmaceutical company, but several large pharmaceutical companies recently reported on developments in this area.

Personalized medicine is still a nascent area for pharmaceutical companies, but several large companies recently reported developments in this area.

GSK Chief Executive Andrew Witty outlined the company's strategic priorities for 2010, which include further diversification into emerging markets, consumer healthcare, and vaccines.

AstraZeneca plans to undertake further restructuring in its R&D operations, resulting in the elimination of 3500 jobs.

AstraZeneca announced this week that it plans to undertake further restructuring in its research and development operations, resulting in the elimination of 3500 jobs.

Growth in emerging markets and across the generic-drug sector shifts the global demand and supply of active pharmaceutical ingredients.

The rising importance of generic drugs, evolving requirements in the ever-more global supply chain, and supplier-management strategies in biologics manufacturing are some key topics to be addressed next month during DCAT Week.

As contract manufacturers and drug companies meet at Informex, the stage is set for the latest in pharmaceutical chemical development.

A look at the formulation challenges in pancreatic enzyme products.

Leading experts share insight on the current and future direction of process analytical technology. This article contains bonus online material.

Johnson & Johnson is recalling a number of products because of reports of an unusual mouldy, musty, or mildew-like odour that has been associated with nausea, stomach pain, vomiting or diarrhea in a small number of cases.

McNeil Consumer Healthcare is voluntarily recalling certain lots of over-the-counter products in the Americas, the United Arab Emirates, and Fiji.